Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Katherine Riccione; Carter M. Suryadevara; David Snyder; Xiuyu Cui; John H. Sampson; Luis Sanchez-Perez

doi:10.3791/52397

JoVE Journal
Immunology and Infection

A subscription to JoVE is required to view this content. Sign in or start your free trial.

JoVE Journal Immunology and Infection

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

CAR性T细胞过继治疗的护理标准胶质母细胞瘤的上下文生成

Full Text

22,113 Views

12:55 min

February 16, 2015

DOI: 10.3791/52397-v

Katherine Riccione^1,2, Carter M. Suryadevara^1,3, David Snyder¹, Xiuyu Cui¹, John H. Sampson^1,2,3, Luis Sanchez-Perez¹

¹Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery,Duke University, ²Department of Biomedical Engineering,Duke University, ³Department of Pathology,Duke University

Please note that some of the translations on this page are AI generated. Click here for the English version.

化疗和放疗标准的淋巴耗干和免疫调节作用可用于增强 T 细胞免疫疗法的抗肿瘤疗效。我们概述了一种生成 EGFRvIII 特异性嵌合抗原受体（CAR） T 细胞并在胶质母细胞瘤标准护理背景下施用它们的方法。

该程序的总体目标是生成转基因嵌合抗原受体小鼠 T 细胞，并在标准护理的背景下评估它们的疗效。对于高级别神经胶质瘤，这是通过首先开始标准护理、全脑放疗和对小鼠的替莫唑胺给药来实现的。接下来，产生表达 car 载体的逆转录病毒，然后用 car 逆转录病毒转导小鼠 T 细胞。

最后，将 CAR T 细胞递送给接受标准护理治疗的小鼠，最终将 CAR T 细胞与全脑照射和替莫唑胺一起递送。给药用于测试通过标准护理进行宿主调节是否能增强过继性 T 细胞平台的疗效。这种方法可以帮助回答脑肿瘤免疫治疗领域的关键问题，例如新型免疫疗法在高级别胶质瘤护理标准背景下的抗肿瘤疗效。

View the full transcript and gain access to thousands of scientific videos

Explore More Videos

癌症生物学第96 肿瘤免疫治疗胶质母细胞瘤嵌合抗原受体过继转移替莫唑胺放疗